The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 544-545

  Ott, M Michaela ^a   Horn, Heike ^b   Kaufmann, Martin ^b   Ott, German ^b  

^a CARITAS KRANKENHAUS   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Diffuse large B cell lymphoma; Hans classifier; Immunohistochemistry; Prognosis

Indexed keywords

CD103 ANTIGEN; CD31 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ANTIGEN SPECIFICITY; B LYMPHOCYTE ACTIVATION; CANCER SURVIVAL; CELLULAR IMMUNITY; EDITORIAL; GENE EXPRESSION PROFILING; GENETIC ALGORITHM; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LMO2 GENE; LONG TERM SURVIVAL; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TNFRSF9 GENE; TUMOR GENE; TUMOR MICROENVIRONMENT;

ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE;

EID: 84858751862     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.01.022     Document Type: Editorial

References (19)

1. Stein H., Warnke R.A., Chan W.C., Jaffe E.S., Chan J.K.C., Gatter K.C., et al. Diffuse large B-cell lymphoma, not otherwise specified. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 233-237. IARP, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002, 346:235-242.
3. Fu K., Weisenburger D.D., Choi W.W., Perry K.D., Smith L.M., Shi X., et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008, 26:4587-4594.
4. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
5. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med 2002, 346:1937-1947.
6. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
7. Choi W.W., Weisenburger D.D., Greiner T.C., Piris M.A., Banham A.H., Delabie J., et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009, 15:5494-5502.
8. Muris J.J., Meijer C.J., Vos W., van Krieken J.H., Jiwa N.M., Ossenkoppele G.J., et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006, 208:714-723.
9. Nyman H., Jerkeman M., Karjalainen-Lindsberg M.L., Banham A.H., Leppä S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 2009, 22:1094-1101.
10. Bernd H.W., Ziepert M., Thorns C., Klapper W., Wacker H.H., Hummel M., et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - comprehensive morphological and immunohistochemical analyses of cases from a large prospective randomized clinical trial. Haematologica 2009, 94(11):1569-1580.
11. Ott G., Ziepert M., Klapper W., Horn H., Szczepanowski M., Bernd H.W., et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010, 116(23):4916-4925.
12. Meyer P.N., Fu K., Greiner T.C., Smith L.M., Delabie J., Gascoyne R.D., et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011, 29:200-207.
13. Castillo J.J., Beltran B.E., Song M.-K., Ilic I., Leppa S., Nurmi H., et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treatment with R-CHOP. Leuk Res 2012, 36(4):413-417.
14. De Jong D., Rosenwald A., Chhanabhai M., Gaulard P., Klapper W., Lee A., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007, 25(7):805-812.
15. Salles G., de Jong D., Xie W., Rosenwald A., Chhanabhai M., Gaulard P., et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011, 117(26):7070-7078.
16. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. New Engl J Med 2008, 359:2313-2323.
17. Meyer P.N., Fu K., Greiner T., Smith L., Delabie J., Gascoyne R., et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 2011, 135:54-61.
18. Cardesa-Salzmann T.M., Colomo L., Climent F., Chan W.C., Weisenburger D., Climent F., et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 2011, 96:996-1001.
19. Alizadeh A.A., Gentles A.J., Alencar A.J., Liu C.L., Kohrt H.E., Houot R., et al. Prediction of survival in diffuse large B cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011, 118:1350-1358.